Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

In a four-year study, Vabysmo (faricimab) was found to be well-tolerated and effective in treating diabetic macular edema (DME). Over 90% of patients had no signs of DME after four years of treatment. Vabysmo sustained vision gains and dried retinal fluid, allowing for extended treatment intervals of three to four months in 80% of patients. The study met all primary safety and efficacy endpoints, with results consistent with Vabysmo's known safety profile. RHONE-X, the largest long-term extension dataset in DME, provides robust evidence of Vabysmo's potential as a standard of care treatment for DME. Vabysmo targets two signaling pathways linked to vision loss, stabilizing blood vessels and improving retinal health. It is approved in nearly 100 countries for DME, wet age-related macular degeneration (nAMD), and macular edema following retinal vein occlusion. Over four million doses of Vabysmo have been distributed worldwide, demonstrating its significant impact on treating retinal conditions.